AnserBio
1 known investors
AnserBio develops an oncology biotherapy that restores functional p53 tumor suppressor protein by delivering it through proprietary cell-derived nanovesicles (exosomes). It targets p53-mutant cancers with high unmet need, including colon, bladder, ovarian cancer, and glioblastoma.
Founders & leadership
LV
Lana VolokhCo-founder
AT
Alex TendlerCo-founder
YT
Yevgeny TendlerCSO
Investors · 1
Frequently asked questions
- What does AnserBio do?
- AnserBio develops an oncology biotherapy that restores functional p53 tumor suppressor protein by delivering it through proprietary cell-derived nanovesicles (exosomes). It targets p53-mutant cancers with high unmet need, including colon, bladder, ovarian cancer, and glioblastoma.
- Who founded AnserBio?
- AnserBio was founded by Lana Volokh, Alex Tendler.
- Who are AnserBio's investors?
- AnserBio's investors include Peregrine Ventures.